Abstract Library

#4483 Metabolic parameters and visceral adiposity index in type 1 gastric neuroendocrine tumours: A single-centre cross-sectional study

Introduction: Studies have shown that the accumulation of visceral fat and the occurrence of metabolic syndrome (MetS) lead to disruptions in immune-metabolic crosstalk, contributing to the development and progression of autoimmune diseases and well-differentiated gastric neuroendocrine tumours (gNETs).

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen R, Wang Y, Wang Y,

Keywords: Type 1 gastric neuroendocrine tumour, Metabolic Syndrome, Visceral Adiposity Index,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,

#3413 Visceral obesity at diagnosis is associated with well-differentiated neuroendocrine neoplasia lower progression free survival

Introduction: The association of well-differentiated gastroenteropancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. Although the role of the intrinsic clinical, pathological, and molecular factors on GEP-NEN prognosis has been extensively studied, the association of adverse outcomes with obesity and metabolic risk factors was not identified so far.

Conference:

Presenting Author: Santos A

Authors: Santos A, Rodrigues J, Henrique R, Cardoso M, Monteiro M,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, metabolic syndrome, visceral obesity, overall survival, progression free survival,

#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Modica R

Authors: Modica R, Barrea L, Bottiglieri F, de Cicco F, Minotta R,

Keywords: GEP-NET, metabolic syndrome, visceral adiposity index, fatty liver index,

#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS

Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pereira R

Authors: Pereira R, Pereira S, Morais T, Costa M, Sampaio P,

Keywords: GEP-NETs, metabolic syndrome, FOXM1, IGF1R, IL-6, Ki67 ,